These findings suggest that pharmacologically inhibiting GSDMD may be clinically efficacious for treating inflammatory diseases such as familial cryopyrin-associated periodic syndromes, autoimmune conditions and gastrointestinal diseases [62]. The gene discussed is GSDMD; the disease is Autoimmunity.